Latest From Alcon Inc.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
Growth prospects for Turkey’s medical technology market are significant, but local companies have complained about public policies that are harmful to business and about the ongoing crisis in the hospital system. Now, international medtechs are starting to react, with some downscaling local operations and portfolios. Association of Research Based Medical Technologies Manufacturers president Umut Gokalp laid out the problems being faced by industry, and what action he thinks the government should take.
Gilead partners with Glympse to optimize NASH trials, while Ironwood will work with Pear on digital therapies for GI disorders. An alliance between Leo and Ubiquigent yields an option agreement around two novel compounds.
The Basel-headquartered company has launched three high-profile drugs in the past couple of months. Analysts are waiting to see what initial impact these potential future growth drivers are having.
- Consumables, Central Supplies
- Implantable Devices
- Surgical Equipment & Devices
- OTC, Consumer
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Alcon Inc.
- Senior Management
David Endicott, CEO
Timothy C Stonesifer, SVP, CFO
Franck Leveiller, SVP, Head, Global R&D
Laurent Attias, Head, Global Corp. Dev. Strategy, BD&L, & M&A
Ed McGough, SVP, Global Mfctng. & Technical Operations
- Contact Info
Avenue Louis-Casaï 58
Cointrin-Geneva, TX CH-1216
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.